大麻使用与精神分裂症及双相障碍的遗传学关联研究
该研究利用全基因组关联汇总数据,估计精神病性障碍与大麻表型的遗传力、多基因性及遗传相关性,发现二者存在正向全局遗传相关(0·22-0·35)及混合局部相关,并鉴定共享位点。因果分析提示精神病性障碍对大麻表型有因果效应,终生大麻使用对双相障碍有因果效应。在挪威队列中,大麻表型多基因评分独立预测精神病性障碍并改善预测。
要点
- 精神病性障碍与大麻表型存在正向全局遗传相关(范围0·22-0·35)。
- 精神病性障碍对大麻表型有因果效应,终生大麻使用对双相障碍有因果效应。
- 大麻表型多基因评分独立预测精神病性障碍并提升预测效能。
核心结论
- 部分个体可能同时具有精神病性障碍和大麻使用的高遗传风险。
- 该发现支持减少大麻使用的公共卫生努力,尤其针对高危个体或精神病性障碍患者。
- 鉴定的共享位点及其功能提示可能促进新治疗开发。
研究设计与样本
- 使用欧洲 ancestry 个体的全基因组关联汇总统计,来源包括 Psychiatric Genomics Consortium、UK Biobank 和 International Cannabis Consortium。
- 估计各表型的遗传力、多基因性和可发现性,并进行全基因组和局部遗传相关分析。
- 鉴定共享位点并映射至基因,进行功能富集分析。
- 利用挪威 Thematically Organized Psychosis 队列(2181 名欧洲参与者)进行因果分析和多基因评分分析。
主要发现
- 精神病性障碍比大麻表型更具遗传力,且比大麻使用障碍更具多基因性。
- 精神病性障碍与大麻表型存在正向全基因组遗传相关(范围0·22-0·35),局部遗传相关有正有负。
- 精神病性障碍与大麻表型配对中鉴定出3至27个共享位点。
- 映射基因的富集涉及神经元和嗅觉细胞,以及尼古丁、酒精和度洛西汀的药物-基因靶点。
- 在挪威队列中(1060名女性[48·6%],1121名男性[51·4%],平均年龄33·1岁[SD 11·8];400例双相障碍,697例精神分裂症,1044例健康对照),大麻表型多基因评分独立预测精神病性障碍,并超越精神病性障碍多基因评分的预测。
关键数值与推荐
- 精神病性障碍与大麻表型的全基因组遗传相关范围为0·22-0·35。
- 精神病性障碍与大麻表型配对鉴定出3至27个共享位点。
- 挪威队列应用多基因风险评分分析的欧洲参与者共2181名,其中女性1060名(48·6%),男性1121名(51·4%),平均年龄33·1岁(SD 11·8)。
- 挪威队列中400例双相障碍,697例精神分裂症,1044例健康对照。
临床怎么用
- 临床可关注精神病性障碍患者及高危个体的大麻使用情况,因其可能与遗传风险共享相关。
- 大麻表型多基因评分可能辅助识别精神病性障碍高风险个体,但需进一步验证。
- 共享位点的功能发现提示潜在新治疗靶点,但尚未转化为临床干预。
局限性
- 研究基于欧洲 ancestry 个体,结果外推至其他人群需谨慎。
- 原文未报告具体的环境混杂因素控制情况。
- 因果分析基于遗传工具变量,可能存在水平多效性等局限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The relationship between psychotic disorders and cannabis use is heavily debated. Shared underlying genetic risk is one potential explanation. We investigated the genetic association between psychotic disorders (schizophrenia and bipolar disorder) and cannabis phenotypes (lifetime cannabis use and cannabis use disorder). METHODS: We used genome-wide association summary statistics from individuals with European ancestry from the Psychiatric Genomics Consortium, UK Biobank, and International Cannabis Consortium. We estimated heritability, polygenicity, and discoverability of each phenotype. We performed genome-wide and local genetic correlations. Shared loci were identified and mapped to genes, which were tested for functional enrichment. Shared genetic liabilities to psychotic disorders and cannabis phenotypes were explored using causal analyses and polygenic scores, using the Norwegian Thematically Organized Psychosis cohort. FINDINGS: Psychotic disorders were more heritable than cannabis phenotypes and more polygenic than cannabis use disorder. We observed positive genome-wide genetic correlations between psychotic disorders and cannabis phenotypes (range 0·22-0·35) with a mixture of positive and negative local genetic correlations. Three to 27 shared loci were identified for the psychotic disorder and cannabis phenotype pairs. Enrichment of mapped genes implicated neuronal and olfactory cells as well as drug-gene targets for nicotine, alcohol, and duloxetine. Psychotic disorders showed a causal effect on cannabis phenotypes, and lifetime cannabis use had a causal effect on bipolar disorder. Of 2181 European participants from the Norwegian Thematically Organized Psychosis cohort applied in polygenic risk score analyses, 1060 (48·6%) were females and 1121 (51·4%) were males (mean age 33·1 years [SD 11·8]). 400 participants had bipolar disorder, 697 had schizophrenia, and 1044 were healthy controls. Within this sample, polygenic scores for cannabis phenotypes predicted psychotic disorders independently and improved prediction beyond the polygenic score for the psychotic disorders. INTERPRETATION: A subgroup of individuals might have a high genetic risk of developing a psychotic disorder and using cannabis. This finding supports public health efforts to reduce cannabis use, particularly in individuals at high risk or patients with psychotic disorders. Identified shared loci and their functional implications could facilitate development of novel treatments. FUNDING: US National Institutes of Health, the Research Council Norway, the South-East Regional Health Authority, Stiftelsen Kristian Gerhard Jebsen, EEA-RO-NO-2018-0535, European Union's Horizon 2020 Research and Innovation Programme, the Marie Skłodowska-Curie Actions, and University of Oslo Life Science.
引用
- Cheng W, Parker N, Karadag N, et al. The relationship between cannabis use, schizophrenia, and bipolar disorder: a genetically informed study. Lancet Psychiatry. 2023. PMID: 37208114. doi:10.1016/S2215-0366(23)00143-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。